Novartis India acquires Pfizer’s Minipress brands for $150 million

{
  "signal_id": "a412f651-7742-64ce-f23a-d0af2ae43d56",
  "signal_type": "news",
  "signal_subtype": "sells_assets_to",
  "detected_at": "2026-09-07T06:46:28+00:00",
  "company": {
    "name": "Pfizer",
    "domain": "pfizer.com"
  },
  "data": {
    "url": "https://www.cnbctv18.com/market/novartis-india-share-price-acquire-minipress-pfizers-high-blood-pressure-drug-rs-1250-crore-19985424.htm",
    "title": "Novartis India to acquire Minipress, Pfizer’s high blood pressure drug, for ₹1,250 crore - CNBC TV18",
    "assets": "intellectual property rights",
    "excerpt": "Novartis India to acquire Minipress, Pfizer’s high blood pressure drug, for ₹1,250 crore Under the agreement, Pfizer will assign the Minipress and Minipres trademarks registered in India, along with certain related intellectual property rights, to Novartis India. The signing and closing of the transaction will take place simultaneously, the company said. By Megha Rani September 7, 2026, 12:16:28 PM IST (Published) 3 Min Read Novartis India said on Monday, September 7, that its board has approved the acquisition of the trademarks 'Minipress' and 'Minipres' registered in India, along with certain related intellectual property rights, from Pfizer Inc, USA, and Pfizer Products Inc, USA. The transaction will involve a total aggregate consideration of ₹1,250 crore, Novartis India said in an exchange filing. Following the board's approval at its meeting held on September 7, Novartis India executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc. and Pfizer Products Inc. for the transaction. Under the agreement, Pfizer will assign the Minipress and Minipres trademarks registered in India, along with certain related intellectual property rights, to Novartis India. The signing and closing of the transaction will take place simultaneously, the company said. According to IQVIA MAT July 2026 data cited by Novartis India, Minipress XL recorded revenue of ₹228.6...",
    "product": "Minipress",
    "summary": "Pfizer Inc. and Pfizer Products Inc. are selling the 'Minipress' and 'Minipres' trademarks and related intellectual property in India to Novartis India for ₹1,250 crore.",
    "location": "India",
    "planning": false,
    "image_url": "https://images.cnbctv18.com/uploads/2026/07/novartis-2026-07-f9295ea4afbbffe748ea1be53c920273.jpeg?im=FitAndFill,width=1200,height=675",
    "confidence": 0.95,
    "product_data": {
      "name": "Minipress",
      "full_text": "high blood pressure drug",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-07T06:46:28Z",
    "location_data": [
      {
        "region": "Southern Asia",
        "country": "India",
        "continent": "Asia",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-07",
    "article_sentence": "Under the agreement, Pfizer will assign the Minipress and Minipres trademarks registered in India, along with certain related intellectual property rights, to Novartis India.",
    "related_company_name": "Novartis India",
    "related_company_domain": "novartis.in"
  }
}

curl https://signals.autobound.ai/v1/signals/a412f651-7742-64ce-f23a-d0af2ae43d56 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"pfizer.com","limit":20}'